The efficacy and safety of silodosin in treating BPH: A systematic review and meta-analysis

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1601-1609

  Cui, Yuanshan ^a   Zong, Huantao ^a   Zhang, Yong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Benign prostate hyperplasia; Meta analysis; RCT; Silodosin

Indexed keywords

PLACEBO; SILODOSIN; TAMSULOSIN; INDOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; HEADACHE; HEART RATE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIDE EFFECT; STORAGE SYMPTOM SCORE; SYSTEMATIC REVIEW; VOIDING SYMPTOM SCORE; REVIEW;

HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84877593063     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0261-6     Document Type: Article

References (18)

1. Lepor H (2005) Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 7(suppl 7):S3-S11
2. Baazeem A, Elhilali MM (2008) Surgical management of benign prostatic hyperplasia: current evidence. Nat Clin pract Urol 5:540-549
3. Wu JP (2004) Wujieping urology. Shangdong Science and Technology Press, Jinan, pp 1143-1170
4. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029-1035
5. 1- adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 3:76-83
6. Tatemichi S, Kobayashi K, Maezawa A, et al. (2006) α1-Adenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126:209-216
7. Akiyama K, Hora M, Tatemichi S, et al. (1999) KMD-3213, a uroselective and long-acting α1A-adenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291:81-91
8. Akiyama K, Noto H, Nishizawa O, et al. (2001) Effect of KMD-3213, an α1A-adenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 8:177-183
9. Yu HJ, Lin ATL, Yang SSD, et al. (2011) Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptom (LUTS) associated with benign prostatic hyperplasia (BPH). BJUI 11:1843-1848
10. Chapple CR, Montorsi F, Tammela TLJ, et al. (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. Eur Uro 3:342-352
11. Marks LS, Gittelman MC, Hill LA, et al. (2009) Rapid efficacy of the highly selective α1A-adenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634-2640
12. Kawabe K, Yoshida M, Homma Y, et al. (2006) Silodosin a new α1A-adenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase three randomized, placebo-controlled, double-blind study in Japanese men. Low Urin Tract BJUI 5:1019-1024
13. Marks LS, Gittelman MC, Hill LA, et al. (2009) Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 74:1318-1322
14. Shibata K, Foglar R, Horie K, et al. (1995) KMD-3213, a novel, potent; α1A-adenoceptor-selective antagonist: characterization using recombinant human α1-adenoceptors and native tissues. Mol Pharmacol 48:250-258
15. Schwinn DA, Roehrborn CG (2008) α1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15:193
16. Schou J, Holm NK, Meyhoff HH (1996) Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 179:119-122
17. Emberton M, Neal DE, Black N, et al. (1996) The effect of prostatectomy on symptom severity and quality of life. Br J Urol 77:233-247
18. Scarpa RM (2001) Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 40(Suppl. 4):12-20